Standard‐dose VKA plus single antiplatelet agent vs vitamin K antagonist (VKA)
Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
Standard‐dose VKA plus single antiplatelet agent showed no clear difference in strokea compared with standard‐dose VKA (low certainty).
1 finding from 1 review
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people… 2020 · Cochrane Headline outcomes onlyRR 4.45 [0.48, 41]1 study · 82 participantsLow